S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
NASDAQ:TGTX

TG Therapeutics Stock Forecast, Price & News

$45.00
+1.23 (+2.81 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.96
Now: $45.00
$45.34
50-Day Range
$43.50
MA: $48.74
$54.30
52-Week Range
$6.34
Now: $45.00
$56.74
Volume924,603 shs
Average Volume1.53 million shs
Market Capitalization$5.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.
TG Therapeutics logo

Headlines

Is TGTX A Good Stock To Buy According To Hedge Funds?
December 21, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484
Employees217
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Price / Sales39,447.00
Book Value$0.39 per share

Profitability

Net Income$-172,870,000.00
Net Margins-151,798.69%

Miscellaneous

Market Cap$5.92 billion
Next Earnings Date3/2/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

130th out of 1,966 stocks

Pharmaceutical Preparations Industry

60th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$45.00
+1.23 (+2.81 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

Is TG Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than TG Therapeutics?

Wall Street analysts have given TG Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TG Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for TG Therapeutics
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Monday, November, 9th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.32. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.04 million. TG Therapeutics had a negative net margin of 151,798.69% and a negative trailing twelve-month return on equity of 223.96%.
View TG Therapeutics' earnings history
.

How has TG Therapeutics' stock been impacted by Coronavirus?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TGTX stock has increased by 349.6% and is now trading at $45.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TGTX?

5 brokers have issued 12 month price objectives for TG Therapeutics' stock. Their forecasts range from $38.00 to $95.00. On average, they anticipate TG Therapeutics' share price to reach $64.00 in the next twelve months. This suggests a possible upside of 42.2% from the stock's current price.
View analysts' price targets for TG Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Mr. Michael S. Weiss, CEO & Pres (Age 55, Pay $827.54k)
  • Mr. Sean A. Power CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 39, Pay $470.56k)
  • Dr. Owen A. O'Connor, Chief Scientific Officer
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (11.28%), BlackRock Inc. (6.51%), Lord Abbett & CO. LLC (3.38%), Price T Rowe Associates Inc. MD (1.07%), Northern Trust Corp (1.03%) and Candriam Luxembourg S.C.A. (0.77%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends for TG Therapeutics
.

Which institutional investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Candriam Luxembourg S.C.A., Barclays PLC, Pier Capital LLC, UBS Asset Management Americas Inc., SG Americas Securities LLC, Federated Hermes Inc., and State of New Jersey Common Pension Fund D. Company insiders that have sold TG Therapeutics company stock in the last year include Ra Capital Management, LP, William James Kennedy, and Yann Echelard.
View insider buying and selling activity for TG Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TG Therapeutics stock?

TGTX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Price T Rowe Associates Inc. MD, BlackRock Inc., Nicholas Investment Partners LP, Renaissance Technologies LLC, Victory Capital Management Inc., Panagora Asset Management Inc., and Morgan Stanley.
View insider buying and selling activity for TG Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $45.00.

How much money does TG Therapeutics make?

TG Therapeutics has a market capitalization of $5.92 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does TG Therapeutics have?

TG Therapeutics employs 217 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

Where are TG Therapeutics' headquarters?

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.